BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 32382008)

  • 1. The USP10-HDAC6 axis confers cisplatin resistance in non-small cell lung cancer lacking wild-type p53.
    Hu C; Zhang M; Moses N; Hu CL; Polin L; Chen W; Jang H; Heyza J; Malysa A; Caruso JA; Xiang S; Patrick S; Stemmer P; Lou Z; Bai W; Wang C; Bepler G; Zhang XM
    Cell Death Dis; 2020 May; 11(5):328. PubMed ID: 32382008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2.
    Tung MC; Lin PL; Wang YC; He TY; Lee MC; Yeh SD; Chen CY; Lee H
    Oncotarget; 2015 Dec; 6(39):41692-705. PubMed ID: 26497680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TNFAIP8 promotes the proliferation and cisplatin chemoresistance of non-small cell lung cancer through MDM2/p53 pathway.
    Xing Y; Liu Y; Liu T; Meng Q; Lu H; Liu W; Hu J; Li C; Cao M; Yan S; Huang J; Wang T; Cai L
    Cell Commun Signal; 2018 Jul; 16(1):43. PubMed ID: 30064446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implications of the USP10-HDAC6 axis in lung cancer - A path to precision medicine.
    Zhang XM; Gavande N; Parajuli P; Bepler G
    J Cancer Biol; 2021; 2(1):. PubMed ID: 34746935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. WP1130 attenuates cisplatin resistance by decreasing P53 expression in non-small cell lung carcinomas.
    Wang X; Bao Y; Dong Z; Chen Q; Guo H; Ziang C; Shao J
    Oncotarget; 2017 Jul; 8(30):49033-49043. PubMed ID: 28446729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Annexin A2 contributes to cisplatin resistance by activation of JNK-p53 pathway in non-small cell lung cancer cells.
    Feng X; Liu H; Zhang Z; Gu Y; Qiu H; He Z
    J Exp Clin Cancer Res; 2017 Sep; 36(1):123. PubMed ID: 28886730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Depletion of HDAC6 enhances cisplatin-induced DNA damage and apoptosis in non-small cell lung cancer cells.
    Wang L; Xiang S; Williams KA; Dong H; Bai W; Nicosia SV; Khochbin S; Bepler G; Zhang X
    PLoS One; 2012; 7(9):e44265. PubMed ID: 22957056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cisplatin-enriching cancer stem cells confer multidrug resistance in non-small cell lung cancer via enhancing TRIB1/HDAC activity.
    Wang L; Liu X; Ren Y; Zhang J; Chen J; Zhou W; Guo W; Wang X; Chen H; Li M; Yuan X; Zhang X; Yang J; Wu C
    Cell Death Dis; 2017 Apr; 8(4):e2746. PubMed ID: 28406482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TRIM65 negatively regulates p53 through ubiquitination.
    Li Y; Ma C; Zhou T; Liu Y; Sun L; Yu Z
    Biochem Biophys Res Commun; 2016 Apr; 473(1):278-282. PubMed ID: 27012201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exosomal Transfer Of Cisplatin-Induced miR-425-3p Confers Cisplatin Resistance In NSCLC Through Activating Autophagy.
    Ma Y; Yuwen D; Chen J; Zheng B; Gao J; Fan M; Xue W; Wang Y; Li W; Shu Y; Xu Q; Shen Y
    Int J Nanomedicine; 2019; 14():8121-8132. PubMed ID: 31632022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiR-488 inhibits proliferation and cisplatin sensibility in non-small-cell lung cancer (NSCLC) cells by activating the eIF3a-mediated NER signaling pathway.
    Fang C; Chen YX; Wu NY; Yin JY; Li XP; Huang HS; Zhang W; Zhou HH; Liu ZQ
    Sci Rep; 2017 Jan; 7():40384. PubMed ID: 28074905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The miR 495-UBE2C-ABCG2/ERCC1 axis reverses cisplatin resistance by downregulating drug resistance genes in cisplatin-resistant non-small cell lung cancer cells.
    Guo J; Jin D; Wu Y; Yang L; Du J; Gong K; Chen W; Dai J; Miao S; Xi S
    EBioMedicine; 2018 Sep; 35():204-221. PubMed ID: 30146342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy.
    Zhang P; Ma Y; Lv C; Huang M; Li M; Dong B; Liu X; An G; Zhang W; Zhang J; Zhang L; Zhang S; Yang Y
    Cancer Sci; 2016 Nov; 107(11):1563-1571. PubMed ID: 27581532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. USP10 regulates p53 localization and stability by deubiquitinating p53.
    Yuan J; Luo K; Zhang L; Cheville JC; Lou Z
    Cell; 2010 Feb; 140(3):384-96. PubMed ID: 20096447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction of microRNA-184 by E6 oncoprotein confers cisplatin resistance in lung cancer via increasing Bcl-2.
    Tung MC; Lin PL; Cheng YW; Wu DW; Yeh SD; Chen CY; Lee H
    Oncotarget; 2016 May; 7(22):32362-74. PubMed ID: 27083050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective targeting p53
    Lu W; Cheng F; Yan W; Li X; Yao X; Song W; Liu M; Shen X; Jiang H; Chen J; Li J; Huang J
    Oncogene; 2017 Aug; 36(33):4719-4731. PubMed ID: 28394340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cisplatin-induced apoptosis in non-small-cell lung cancer cells is dependent on Bax- and Bak-induction pathway and synergistically activated by BH3-mimetic ABT-263 in p53 wild-type and mutant cells.
    Matsumoto M; Nakajima W; Seike M; Gemma A; Tanaka N
    Biochem Biophys Res Commun; 2016 Apr; 473(2):490-6. PubMed ID: 26996126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
    Gong H; Li Y; Yuan Y; Li W; Zhang H; Zhang Z; Shi R; Liu M; Liu C; Chen C; Liu H; Chen J
    BMC Cancer; 2020 Dec; 20(1):1189. PubMed ID: 33276757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of a novel HDAC/RXR/HtrA1 signaling axis as a novel target to overcome cisplatin resistance in human non-small cell lung cancer.
    Wang W; Zhao M; Cui L; Ren Y; Zhang J; Chen J; Jia L; Zhang J; Yang J; Chen G; Ashby CR; Wu C; Chen ZS; Wang L
    Mol Cancer; 2020 Sep; 19(1):134. PubMed ID: 32878625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting MALAT1 induces DNA damage and sensitize non-small cell lung cancer cells to cisplatin by repressing BRCA1.
    Huang J; Lin C; Dong H; Piao Z; Jin C; Han H; Jin D
    Cancer Chemother Pharmacol; 2020 Nov; 86(5):663-672. PubMed ID: 33030583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.